NCT06645821View on ClinicalTrials.gov

Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 3, 2024

Primary Completion Date

March 31, 2025

Study Completion Date

May 31, 2025

Conditions
Hidradenitis Suppurativa (HS)
Interventions
DRUG

EVO101

EVO101 topical cream 0.1%

Trial Locations (1)

23502

RECRUITING

Virginia Clinical Research, Inc., Norfolk

Sponsors

Collaborators (1)

Evommune, Inc.
All Listed Sponsors
collaborator

Evommune, Inc.

INDUSTRY

lead

Virginia Clinical Research, Inc.

OTHER